Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Biomarker study for patients with metastatic colorectal cancer treated with anti-angiogenic agent using liquid biopsy

ABSTRACT: Primary outcome(s): Association of RAS, BRAF, PIC3CA, and EGFR gene mutations in liquid biopsy with chemotherapy efficacy and prognosis of colorectal cancer

DISEASE(S): Colorectal Cancer

PROVIDER: 2660136 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multi-parametric liquid biopsy approach

Project description:Multi-parametric liquid biopsy approach

| PRJEB39331 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887892 | ENA

Retinoblastoma Aqueous Humor Liquid Biopsy Repository

Project description:Retinoblastoma Aqueous Humor Liquid Biopsy Repository

| PRJNA887893 | ENA

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Project description:This study is a prospective, randomized phase III, to evaluate if in patients with mCRC RAS/BRAF wild type on tumor tissue and RAS mutations on liquid biopsy, treating in first line with antibody anti-VEGF (bevacizumab) plus chemotherapy (FOLFIRI) is superior in terms of PFS compared to standard treatment with antibody anti-EGFR (cetuximab) plus FOLFIRI, and then in patients RAS/BRAF wild type on tumor tissue who develop RAS mutations on liquid biopsy after the beginning of the first line treatment with cetuximab plus FOLFIRI, in the absence of a clinical or radiological progression disease, to anticipate a change of treatment with bevacizumab plus FOLFIRI further impacts on the PFS.

| 2369067 | ecrin-mdr-crc

Diagnostic accuracy of liquid biopsy in endometrial cancer

Project description:Diagnostic accuracy of liquid biopsy in endometrial cancer

| PRJNA767010 | ENA

SOURCE OF LIQUID BIOPSY BIOMARKER: EXOSOME VS WHOLE PLASMA, FASTING VS NON-FASTING

Project description:SOURCE OF LIQUID BIOPSY BIOMARKER: EXOSOME VS WHOLE PLASMA, FASTING VS NON-FASTING

| PRJNA894213 | ENA

Pre-analytical factors affecting the establishment of a single tube assay for multi-parameter liquid biopsy detection in melanoma patients

Project description:NGS liquid biopsy sequencing of miRNAs in total plasma and EV-associated miRNAs

2020-03-10 | GSE143231 | GEO

Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy.

Project description:Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy.

| PRJNA762369 | ENA

Statistical algorithm enabled high precision tumor biomarker discovery for circulating extracellular vesicle-based cancer liquid biopsy

Project description:Circulating extracellular vesicles (EVs) have gained significant attention for discovering tumor biomarkers. However, isolating EVs with well-defined homogeneous populations from complex biological samples is challenging. Different methods have been found to derive different EV populations carrying different biomolecules, which significantly confound biomarker discovery for developing clinical diagnostics. Building a rigorous EV isolation and standardizing assessment platform associated with -omics is essential to overcome this challenge. We introduced a novel isolation approach using a pH-responsive peptide conjugated with NanoPom magnetic beads (ExCy) for homogeneous EV isolation. Additionally, we introduced the first statistical algorithm for EV quality assessment (ExoQuality Index, EQI), which enables multi-assay quantification to provide a consistent and accurate definition of EV purity and quality; ExoQuality’s algorithm intakes multi-assay information to deconvolute complex EV heterogeneity. We analyzed our next generation sequencing on EV RNAs from pancreatic cancer patient plasma using four isolation methods; results highlighting ExCy’s isolation and EQI assessment improved biomarker identification. We identified a novel EV tumor biomarker, ATP6V0B, validated with Quantitative PCR (qPCR) by screening a pilot cohort of 23 individuals. With random forest modeling the ATP6V0B cycling threshold, we reported an AUC of 0.91, showcasing an enabling and clinically translatable liquid biopsy approach using circulating EVs.

2024-01-31 | GSE246925 | GEO

Statistical algorithm enabled high precision tumor biomarker discovery for circulating extracellular vesicle-based cancer liquid biopsy

Project description:Statistical algorithm enabled high precision tumor biomarker discovery for circulating extracellular vesicle-based cancer liquid biopsy

| PRJNA1035112 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data